Suzhou Alphamab Co., Ltd.

Quick facts

Phase 3 pipeline

• KN057 · Oncology
  KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.

Phase 2 pipeline

• KN057 dose Ⅱ
• KN060 Hight
• KN060 Low · Oncology
  KN060 Low is a monoclonal antibody targeting PD-L1.
• KN060 Middle

Phase 1 pipeline

• KN060
• KN069

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Suzhou Alphamab Co., Ltd. portfolio CI brief
• Suzhou Alphamab Co., Ltd. pipeline updates RSS